Replies to post #164148 on Amarin Corp Plc (AMRN)

[marzan]

Oldyeller, securing Anchor label will allow us to reach out the general public thru DTC ads where Amarin can publicly say cardioprotective language including reduction of heart attack and CVD reductions by 25% and so forth. Presently they are not doing it scared of FDA enforcement action. This will be humongous reaching out to the consumers while in the interim sNDA for RIt can be in process both here and in the Europe. Anchor control required us to provide CVD evidence and the Anchor voting question was about cardioprotctive. So by obtaining Anchor label, Amarin can do DTC commercials directly to the public on the efficacy of V in CVDs. Please ask Elizabeth are they pursuing? if not, why they are NOT pursuing Anchor. Give them your valuable FDA regulatory guidance from your past FDA experience. If thy get Anchor label, DTC commercials on CVD prevention is unlimited, imo.

Anchor label will ensure no enforcement fear from FDA.

[Biobillionair]

It appears Amarin is in “talks” that may have uttered the words “hostile takeover”... I speculate this due to recent dilution and apparent shelf registry of 200,000,000 shares. Amarin only needs 200 million shares for one reason “posion pill defense”. I’ll go a step further and say AZN is likely mouthing off.
BB